Grifols Faces Scrutiny Over Canadian Plasma Donor Deaths

0:00It's April 4th. This is Calgary News today, AI-powered stories from your city. I'm Cory with the story. Spanish drug maker Gryffles is now under tight restrictions on his Canadian license for collecting blood plasma after two donors died following. Donations at their Winnipeg Centers, one in October, and one in January. Health Canada slapped terms and conditions on the company's blood establishment license, pointing to recurring systemic issues across multiple sites, including non-compliance ratings for their Oakville Head Office and Centers in Calgary and Regina. Health Canada hasn't linked the deaths directly to the plasma collection process yet, but they did spot problems in demanded fixes. One donor suing Gryffles over alleged kidney damage from faulty equipment. To enforce better safety, regulators are making the company cut back on appointments at all 16 plasma sites so staff can stick to procedures and ramp up quality checks. People says they're moving fast to fix these deficiencies and fully cooperating with

1:00health Canada, stressing that donor safety is their top priority, and all centers stay open. The company even had their Canadian sales VP, testified before lawmakers recently, on plasma issues after the deaths when public. Inspections turned up lapses like poor donor screening, shaky equipment maintenance in Calgary and Regina, and not enough trained staff at head. This but officials say plasma quality wasn't compromised. Those checks are still going on. Meanwhile, Canada stands out as one of the few spots paying plasma donors, and Gryffles is eyeing a big move by listing its U.S. Biopharmate Unit 2. Raised up to $5 billion in tackle debt, keeping the spotlight on their global ops.